Table 1 Comparison of patients with narcolepsy and definite cataplexy with and without detectable CSF hypocretin‐1 levels.
| CSF hypocretin‐1 undetectable | CSF hypocretin‐1 detectable | |
|---|---|---|
| n | 12 | 6 |
| Age | 37.3±16.4 | 34.3±8.6 |
| Males | 4/12 | 3/6 |
| ESS score | 16.5±3.8 | 15.2±3.1 |
| SPAS score | 10.0±3.5 | 9.1±1.9 |
| UNS score | 23.9±5.9 | 20.4±6.0 |
| SNS score | −35.5±28.5 | −5.0±23.0 |
| Severity of cataplexy | 1: n = 4, 2: n = 4, | 1: n = 3, 2: n = 2, |
| (see text) | 3: n = 4 | 3: n = 1 |
| Frequency of cataplexy | 1: n = 4, 2: n = 3, | 1: n = 1, 2: n = 4, |
| 3: n = 5 | 3: n = 1 | |
| Sleep paralysis | 6/12 | 4/6 |
| Hallucinations | 6/12 | 4/6 |
| HLA DQB1*0602 positive | 10/11 | 5/6 |
| Sleep latency on PSG | 3.3±2.9 | 7.3±5.2 |
| Sleep efficiency on PSG (%) | 91±8 | 94±8 |
| ⩾2 SOREMPs on MSLT | 11/11 | 3/6 |
| MSL on MSLT | 1.4±0.8 min | 3.5±1.9 min |
| MSL on MSLT <5 min | 11/11 | 4/6 |
ESS, Epworth Sleepiness Scale; MSL, mean sleep latency; SNS, Swiss narcolepsy scale; SOREMPs, sleep onset REM periods; SPAS, Sleep Propensity during Active Situations (see text); UNS, Ullanlinna Narcolepsy Scale.